Product name: Degarelix

Synonyms: uglypeptide1,

Sequence: Ac-D-2-Nal-D-4-Cpa-D-3-Pal-Ser-4-Aph(l-Hor)-D-4-Aph(Cbm)-Leu-Lys(Ipr)-Pro-D-Ala-NH2

Purity: 95% by HPLC

Counter ion: Trifluoacetate

Format: Lyophilized powder

Description: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. FDA approved on December 24, 2008. Degarelix has been shown in animal studies to antagonize GnRH receptors in the pituitary gland, resulting in a significant reduction in circulating LH and a subsequent decrease in the synthesis of testosterone. Pharmacokinetic analysis suggests that upon subcutaneous administration, degarelix forms a gel depot, from which the drug then distributes to the rest of the body in a first-order manner.

Uniprot ID: 16136245

Usage: For Scientific Research Use Only, Not for Human Use.

Reference:

Urology, Volume 83, Issue 5, May 2014, Pages 1122-1128.

European Urology, Volume 66, Issue 4, October 2014, Pages 655-663.

Clinical Therapeutics, Volume 31, Part 2, 2009, Pages 2312-2331.

European Urology, Volume 54, Issue 4, October 2008, Pages 805-815.